These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France. Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R; HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860 [TBL] [Abstract][Full Text] [Related]
43. Modelling the influence of activation-induced apoptosis of CD4+ and CD8+ T-cells on the immune system response of a HIV-infected patient. Stan GB; Belmudes F; Fonteneau R; Zeggwagh F; Lefebvre MA; Michelet C; Ernst D IET Syst Biol; 2008 Mar; 2(2):94-102. PubMed ID: 18397120 [TBL] [Abstract][Full Text] [Related]
45. Brazilian HIV-infected population: assessment of the needs of endodontic treatment in the post-highly active antiretroviral therapy era. de Brito LC; da Rosa MA; Lopes VS; e Ferreira EF; Vieira LQ; Sobrinho AP J Endod; 2009 Sep; 35(9):1178-81. PubMed ID: 19720212 [TBL] [Abstract][Full Text] [Related]
46. Comprehensive longitudinal analysis of hepatitis C virus (HCV)-specific T cell responses during acute HCV infection in the presence of existing HIV-1 infection. van den Berg CH; Ruys TA; Nanlohy NM; Geerlings SE; van der Meer JT; Mulder JW; Lange JA; van Baarle D J Viral Hepat; 2009 Apr; 16(4):239-48. PubMed ID: 19222746 [TBL] [Abstract][Full Text] [Related]
47. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639 [TBL] [Abstract][Full Text] [Related]
48. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262 [TBL] [Abstract][Full Text] [Related]
50. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. López A; van der Lubbe N; Sánchez-Palomino S; Arnedo M; Nomdedeu M; Castro P; Guilà M; Maleno MJ; García F; Gallart T; Gatell JM; Plana M Vaccine; 2009 Oct; 27(44):6166-78. PubMed ID: 19712765 [TBL] [Abstract][Full Text] [Related]
51. Vaccines for HIV--looking to the future. TreatmentUpdate; 2004 Oct; 16(6):1-3. PubMed ID: 17219677 [No Abstract] [Full Text] [Related]
54. Immune-based therapies at the retrovirus conference. Raymond D Posit Aware; 2003; 14(3):16-7. PubMed ID: 12866485 [No Abstract] [Full Text] [Related]
55. Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects. Fisher AK; Voronin Y; Jefferys R Vaccine; 2014 Sep; 32(43):5540-5. PubMed ID: 24968157 [No Abstract] [Full Text] [Related]
56. I think I CAM: use of complementary and alternative medicine by PHAs. TreatmentUpdate; 2001; 12(12):18. PubMed ID: 11570086 [No Abstract] [Full Text] [Related]
57. Managing fatigue in HIV/AIDS. Rabkin J Body Posit; 2006; 19(1):34-7. PubMed ID: 16718874 [No Abstract] [Full Text] [Related]
58. Looking for the perfect challenge. von Bubnoff A IAVI Rep; 2009; 13(4):9-13. PubMed ID: 20225575 [No Abstract] [Full Text] [Related]
59. Report from the 12th Retrovirus Conference. Immune-based therapies for established HIV infection. Henry K AIDS Clin Care; 2005 Apr; 17(4):35-6. PubMed ID: 15877316 [No Abstract] [Full Text] [Related]
60. Antiretroviral rounds. Entrance left: the endocrinologist. Hicks CB; Nagy GS; Koutkia-Mylonakis P AIDS Clin Care; 2006 Feb; 18(2):18-9. PubMed ID: 16555392 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]